Hammond Janet MJ 4

What Happened

• Janet Hammond, Chief Development Officer at Atea Pharmaceuticals (AVIR), had a large grant/vesting event and conversions of derivatives on January 31, 2026. The filing shows a 177,000-share award/RSU acquisition and multiple derivative exercise/conversion entries. To cover tax withholding, 14,136 shares were surrendered/sold at $4.24 per share for $59,937.
• The report also lists exercise/conversion activity (separate derivative entries of 58,050 shares acquired and 46,800 and 11,250 shares marked as disposed at $0.00), indicating conversion/settlement of previously granted derivative awards or RSUs/PSUs that vested on that date.

Key Details

• Transaction date: January 31, 2026; Form 4 filed February 3, 2026.
• Tax withholding: 14,136 shares disposed at $4.24 = $59,937 (marked as code F).
• Awards/vesting: 177,000 shares reported as a grant/award or RSU conversion (code A / M) at $0.00 (derivative settlement).
• Other derivative entries: 58,050 shares acquired (M), and disposals of 46,800 and 11,250 shares (M) reported at $0.00.
• Footnotes: F1 = each RSU equals one share; F3/F4 = original RSUs and performance RSUs vested as of Jan 31, 2026; F2 = includes 2,363 shares from the 2020 ESPP; F5 notes an option grants vesting monthly after Jan 31, 2026.
• Shares owned after the reported transactions: not specified in the provided excerpt of the filing.
• Filing timeliness: Form filed Feb 3, 2026 reporting Jan 31 transactions; the filing shows no late-filing flag in the provided data.

Context

• This appears to be a routine vesting/settlement of restricted stock units and performance awards, not an open-market purchase or discretionary sale. The sale of 14,136 shares was to satisfy tax withholding on the vesting/settlement (common with RSU/PSU vesting).
• Derivative entries at $0.00 typically reflect conversion/settlement of RSUs or performance awards rather than a cash purchase; F1–F4 clarify these are RSU/performance-RSU related events.
• For retail investors: the event is primarily an insider receiving vested/awarded shares (a non-cash, compensation-related acquisition) with a small, routine share disposition to cover taxes — not necessarily a signal of buying or selling intent in the open market.